Systematic (IUPAC) name
Clinical data
Trade names Asendin
AHFS/ monograph
MedlinePlus a682202
Pregnancy cat. C(US)
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Bioavailability  ?
Metabolism Hepatic (cytochrome P450 system)
Half-life 8-10 hours (30 hours for major metabolites)
Excretion Renal
CAS number 14028-44-5 YesY
ATC code N06AA17
PubChem CID 2170
IUPHAR ligand 201
DrugBank APRD00142
ChemSpider 2085 YesY
KEGG D00228 YesY
Chemical data
Formula C17H16ClN3O 
Mol. mass 313.781
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Amoxapine (Amokisan, Asendin, Asendis, Defanyl, Demolox, Moxadil) is a tetracyclic antidepressant (TeCA) of the dibenzoxazepine class, though some authorities classify it as a secondary amine tricyclic antidepressant.



Amoxapine is used in the treatment of depression, anxiety disorders, panic disorder, and bipolar disorder. Amoxapine is contra indicated in children because it lowers the seizure threshold to the extent that fits may be precipitated, especially in children. Cardiovascular effects and anti-cholinergic side effects are much reduced. It also has action similar to an atypical antipsychotic.[1]


Amoxapine is a strong norepinephrine reuptake inhibitor and weak serotonin reuptake inhibitor. It also possesses antiadrenergic, anticholinergic, antidopaminergic, antihistamine, and antiserotonergic actions.

Side effects

One of its major metabolites, 7-hydroxyamoxapine, has a dopamine receptor blocking effect, making this drug a common cause of neuroleptic malignant syndrome. Amoxapine is also associated with acute extrapyramidal symptoms and tardive dyskinesia.

Special precautions

Mania, hypomania, severe liver damage, diabetes, myocardial infarction, epilepsy.[clarification needed]

Drug Interactions

potential sedative effects of alcohol, antiparkinson, agents, reduce effects of sympathomimetics.

See also


  1. ^ Apiquian R, Fresan A, Ulloa RE, et al. (December 2005). "Amoxapine as an atypical antipsychotic: a comparative study vs risperidone". Neuropsychopharmacology 30 (12): 2236–44. doi:10.1038/sj.npp.1300796. PMID 15956984. 

Further reading

  • Mosby Year-Book, Inc. (1995). Physician's GenRx: The Complete Drug Reference (5th Ed.). Riverside, CT: Denniston Publishing Co.
  • Palfai, T. & Jankiewicz, H. (1997). Drugs and Human Behavior (2nd Ed.). Madison, WI: Brown & Benchmark.
  • Hedges, D. & Burchfield, C. (2006). Mind, Brain, and Drug: An Introduction to Psychopharmacology. Boston, MA: Pearson.